Metabolic Disease News and Research

RSS

GI Dynamics to present additional results of mechanisms of actions clinical study

GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced that additional results from a previously reported clinical study regarding mechanisms of action will be presented on Saturday, August 29, 2009 by Manoel Galvao Neto, M.D., scientific coordinator, Gastro Obeso Center, Sao Paulo, Brazil and lead investigator for the study, at the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) 14th World Congress in Paris, France.

27 Aug 2009

Patients with Phenylketonuria face increased risk of developing severe neurological complications

Genetic researchers at Children's Memorial Hospital, Chicago, are aggressively identifying adult patients who suffer from the genetic disorder, Phenylketonuria (PKU), and are presenting those findings at the 11th International Congress of Inborn Errors of Metabolism in San Diego, August 29 through September 2.

26 Aug 2009

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

Results of a Schering-Plough Corporation Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability.

12 Mar 2009

Discovery of new gene that causes Leber congenital amaurosis and retinitis pigmentosa

The team of Dr. Robert Koenekoop which includes Dr. Irma Lopez from the Research Institute of the MUHC at the Montreal Children's Hospital played a crucial role in the international collaboration that led to the discovery of a new gene that causes Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP), two devastating forms of childhood blindness.

5 Mar 2009

Overactive brain enzyme may play role in preventing weight gain and obesity

Researchers at Albert Einstein College of Medicine of Yeshiva University have found that overactivity of a brain enzyme may play a role in preventing weight gain and obesity.

14 Dec 2008

Helping diabetics through the holiday season

November ushers in American Diabetes Month - not only a time to be thankful for bustling basic and clinical research underway on the disease, but also the unofficial start of the holiday season.

20 Nov 2008

NicOx's Naproxcinod shows highly significant reduction in daytime blood pressure versus Naproxen

NicOx S.A. has announced that a new analysis of the data from the 104 Ambulatory Blood Pressure Monitoring (ABPM) study for naproxcinod was presented yesterday at the American Heart Association Scientific Sessions 2008, in New Orleans, USA.

12 Nov 2008

Obesity reality check

Sydney University's Institute of Obesity, Nutrition & Exercise (IONE) will today draw together some of Australia's leading obesity experts to review and measure the effectiveness of our response as a nation to the obesity epidemic.

27 Oct 2008

Discovery offers new understanding of diabetes drug target

Scientists at the University of Leicester have published findings about a new advance in the study of major diabetes drug target.

25 Sep 2008

Healthy individuals may be at risk for heart disease

In the face of a growing obesity epidemic in the United States, researchers at Wake Forest University Baptist Medical Center have new study results that indicate that how much fat a person has is not as important as where that fat is located when assessing risk for cardiovascular events and metabolic disease.

8 Sep 2008

How fat, less important than where that fat is!

The latest research from the U.S. says how fat a person is may be less important than where that fat is.

8 Sep 2008

NicOx updates on PF-03187207 and research collaboration with Pfizer

NicOx S.A. has announced the results of a dose-ranging phase 2 study conducted with PF‑03187207 in Japanese patients with glaucoma by its partner Pfizer Inc. PF-03187207 is a nitric oxide-donating prostaglandin analog. The study was designed to compare the safety and efficacy of several doses of PF-03187207 to Xalatan (latanoprost) and enrolled 112 Japanese patients with primary open-angle glaucoma or ocular hypertension.

25 Aug 2008

Research finds a role for the GABA neurotransmitter in maintaining energy balance

Controlling body weight is a complicated process, as any frustrated dieter might attest. But as scientists continue to investigate the brain's intricate neurocircuitry and its role in maintaining energy balance, they are forming a clearer picture of the myriad events that lead to weight gain and weight loss.

10 Aug 2008